Oncolytics extends Cobra agreement
UK-based Cobra Biomanufacturing an international manufacturer of biopharmaceuticals, has extended its agreement with Oncolytics Biotech to provide additional cGMP production and clinical trial supply material of Reolysin.
UK-based Cobra Biomanufacturing an international manufacturer of biopharmaceuticals, has extended its agreement with Oncolytics Biotech to provide additional cGMP production and clinical trial supply material of Reolysin.
This anticancer product is a proprietary formulation based on the Reovirus and has shown promising results in Phase I clinical trials. The value of the agreement is in excess of £750,000 for 2005.
David Thatcher, CEO of Cobra, said: 'I am delighted that we have been successfully re-appointed by Oncolytics Biotech and we very much look forward to continuing our relationship. This agreement further endorses our ability to both manufacture challenging viral products, as well as build a North American customer base. We wish Oncolytics every success in their next clinical trials and will do all we can by supplying high quality product to meet their timelines.'
Brad Thompson, President and CEO of Oncolytics Biotech, commented: 'Advancing and expanding our human clinical trials in 2005 is driving our need for further supply. We are pleased with the work done for us by Cobra to date, and so going back to them for further, extended supply was an obvious decision.'